Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
A milestone for Tmalin
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Astra's clash of the T-cell engager Titans
The Titan CD8-guiding technology seems to have spawned a new variant.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The month ahead: October’s upcoming events
ESMO and the Triple Meeting approach.
